

University of Maryland Health Partners may add or remove drugs from its formulary at any time as part of its Drug Use Management Program. We will immediately remove any drug from our formulary that is deemed by the Food and Drug Administration to be unsafe or, the drug's manufacturer removes the drug from the market.

The following formulary changes were reviewed and approved by the Pharmacy & Therapeutic Committee or added/removed from the formulary based on pharmacy policy. Changes will take effect on **July 1, 2020**.

Drug Name	Therapeutic Class	Add/Remove	Edit Description	Formulary Status
Atripla	Antiretroviral	Remove		
Delstrigo	Antiretroviral	Remove		
Dovato	Antiretroviral	Remove		
Fuzeon	Antiretroviral	Remove		
Juluca	Antiretroviral	Remove		

**NOTE: This table outlines upcoming changes to our formulary that may impact your patients.**

Legend: PA = Prior Authorization, SP = Specialty, QL = Quantity limit, OTC = Over-the-Counter, F = Formulary, AL = Age Limit

**What if my patient will be adversely affected by the formulary change?** We recognize the unique aspects of patients' cases. If for medical reasons your University of Maryland Health Partners patient cannot be converted to a formulary alternative, you can download a **Non-Formulary/Brand Medically Necessary Drug Exception Form** from our website at [www.umhealthpartners.com](http://www.umhealthpartners.com) and fax the completed form to our Pharmacy Department for review.

**What if I need further assistance?** Call the Provider Line at 1-800-730-8543 and follow the voice prompts for the option that will address your service needs.